Michele Mahone

Michele Mahone

Auto-generated profile, based on publicly available information

Michele Mahone

Division of Internal Medicine and Obstetrical Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
SGSophie Grandʼmaison
Sophie Grandʼmaison
NSNadine Sauvé
Nadine Sauvé
FWFlorence Weber
Florence Weber
MDMichel Dagenais
Michel Dagenais
MDMadeleine Md Durand
Madeleine Md Durand
MMMichèle Md Mahone
Michèle Md Mahone
OBJECTIVE: Rupture of hepatic hematoma associated with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome is a catastrophic complication of pregnancy. Maternal and fetal mortality rates are still high despite advances in diagnosis and treatment. We aimed to present our experience at two referral centers for hepatic disease and to compare it with cases from the literature. METHODS: We reviewed nine cases that occurred over the past 6 years in our centers and made an extensive literature review covering the past 10 years. We reviewed and compared multiple outcomes for all these cases. RESULTS: The median maternal age of our patients was 29 years (interquartile range 27–32). Embolization treatment was used with seven of nine (78%) of our patients compared with 5 of 88 (6%) in the literature (P<.001). Our maternal and fetal mortality rates were 0% (95% confidence interval [CI] 0–34%) and 30% (95% CI 7–65%), respectively, compared with 17% (95% CI 10–26%) and 38% (95% CI 31–52%]) from our review of the literature from 2000 to 2010. CONCLUSION: The use of hepatic artery embolization to address hepatic rupture associated with HELLP syndrome may help minimize morbidity and maternal mortality. LEVEL OF EVIDENCE: III

19 September 2018 in Obstetric Medicine
Verified
Journal Article
Closed access
PDF file
MTMarie-Lou Tardif
Marie-Lou Tardif
MMMichèle Mahone
Michèle Mahone
Objective: To investigate the impact of medical and obstetric complications associated with mixed connective tissue disease (MCTD) in pregnancy. Method: We analyzed 68 pregnancies from a systematic literature review and 12 pregnancies affected by MCTD at our centre between 1986 and 2015 for medical and obstetric complications. Results: During pregnancy 37.1% had active MCTD and 26.7% had relapsed. Maternal complications included caesarean section (31.1%, n = 19), preeclampsia (17.6%, n = 13), thromboembolism events, and death (2.5%, n = 2 for each). Fetal complications included prematurity (48.1%, n = 25), intrauterine growth restriction (38.3%, n = 19), and neonatal lupus (28.6%, n = 18, including chondrodysplasia punctata). More than half ( n = 10) of the neonatal lupus cases were explained by anti-U 1 RNP only. The perinatal mortality rate was 17.7% ( n = 14). Pregnant women with active disease had higher rates of prematurity (OR = 7.60; 95%CI [1.93; 29.95]) and perinatal death (OR = 16.83; 95%CI [1.90; 147.70]). Conclusion: MCTD in pregnancy puts women at risk of medical and obstetric complications, and disease activity probably increases this risk.

6 July 2020 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
GCGabrielle Md Côté-Poirier
Gabrielle Md Côté-Poirier
NBNazila Md Bettache
Nazila Md Bettache
ACAnne-Marie Md Côté
Anne-Marie Md Côté
MMMichèle Md Mahone
Michèle Md Mahone
FMFrancine Morin
Francine Morin
NSNadine Md Sauvé
Nadine Md Sauvé
OBJECTIVE: To evaluate complications associated with early postpartum therapeutic anticoagulation. METHODS: A multicenter retrospective cohort study was done to evaluate the association between therapeutic anticoagulation postpartum and major complications (hemorrhagic and wound complications). Secondary outcomes included minor complications, risk factors associated with total complications (including the time to therapeutic anticoagulation resumption after delivery) and recurrent thrombotic events within 6 weeks postpartum. RESULTS: From 2003 to 2015, 232 consecutive women were treated with therapeutic anticoagulation within 96 hours postpartum; among those treated, 91 received unfractionated heparin, 138 received low-molecular-weight heparin, and three received other anticoagulants. The primary outcome, a composite of major hemorrhagic complications (requiring transfusion, hospitalization, volume resuscitation, transfer to intensive care unit, or surgery) and major wound complications, occurred in 7 of 83 (8.4%) for cesarean deliveries and 9 of 149 (6.0%) for vaginal deliveries (P=.490). Total complications (including major and minor hemorrhagic and wound complications) occurred in 13 of 83 (15.7%) for cesarean deliveries compared with 9 of 149 (6.0%) for vaginal deliveries (P=.016). When comparing cases associated with and without complications, the median delay before resuming anticoagulation was significantly shorter for both cesarean (12 vs 33 hours, P=.033) and vaginal deliveries (6 vs 19 hours, P=.006). For vaginal deliveries, 8 of 51 (15.7%) women had complications when anticoagulation was started before 9.25 hours postpartum, compared with 1 of 98 (1.0%) when started after 9.25 hours. For cesarean deliveries, 7 of 21 (33.3%) of women experienced complications compared with 6 of 62 (9.7%) if anticoagulation was started before or after 15.1 hours, respectively. Two (0.9%) episodes of venous thromboembolism occurred within 6 weeks postpartum. CONCLUSION: Among postpartum women who received early therapeutic anticoagulation, major complications occurred in 8.4% for cesarean deliveries and 6.0% for vaginal deliveries. Complications were associated with earlier resumption of therapeutic anticoagulation, particularly before 9.25 hours for vaginal deliveries and before 15.1 hours for cesarean deliveries.

1 October 2011 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
GLGeneviève Létourneau
Geneviève Létourneau
AAAmal Md Abdel-Baki
Amal Md Abdel-Baki
SDSimon Dubreucq
Simon Dubreucq
MMMichele Mahone
Michele Mahone
BGBéatrice Granger
Béatrice Granger

7 March 2018 in Obstetric Medicine
Verified
Journal Article
Closed access
JCJean-Maxime Côté
Jean-Maxime Côté
RMRosalie-Sélène Meunier
Rosalie-Sélène Meunier
JTJan-Alexis Tremblay
Jan-Alexis Tremblay
FWFlorence Weber
Florence Weber
MMMichèle Mahone
Michèle Mahone
Henoch-Schonlein purpura is a relatively common pediatric vasculitis. Very few cases of Henoch-Schonlein purpura during pregnancy have been described. Henoch-Schonlein purpura is variable in its presentation, from completely benign to possibly catastrophic complications. This rarely encountered condition in adults can also be a recurrence of a previous childhood disease. We present a case of a pregnant 40-year-old woman with Henoch-Schonlein purpura, resulting in a viable birth with no fetal complications. Her presentation is discussed in detail and a general presentation of Henoch-Schonlein purpura is explored, with particular attention to its rare onset during pregnancy.

8 May 2025 in Obstetric Medicine
Verified
Journal Article
Closed access
LBLaurence Bourque
Laurence Bourque
MMMichèle Mahone
Michèle Mahone
Objective: We present clinical features and outcomes of second-trimester acute fatty liver of pregnancy (AFLP), a serious but rare condition. Results: Fourteen pregnant women with AFLP or compatible biopsy were identified in the literature. Diagnosis occurred between 20 and 27 + 6 weeks of gestational age. In total, 50% were primigravid. Thirteen cases met the Swansea criteria while the other case had a compatible liver biopsy. In total, 10 out of 11 cases had microvesicular steatosis on their liver biopsy. Common maternal complications included acute renal failure, hypoglycaemia, liver failure, encephalopathy, intensive care unit admission and need for blood transfusions. Seven deliveries were on the day of diagnosis, five within four weeks, and two within three months. One maternal death, seven fetal deaths and three neonatal deaths occurred. Conclusion: AFLP diagnosed in the second trimester is a rare condition. Neonatal mortality and maternal morbidity are high. Most cases had nonspecific symptoms and clinical findings, but a majority had compatible biopsies.